Rhizoma Corydalis is often used as an anauxiliary drug in the compound treatment of tenosynovitis.However,the mechanism of Rhizoma Corydalis in tenosynovitis is still unclear.This study focused the network pharmacology and molecular docking to explore the mechanism of Rhizoma Corydalis in the treatment of tenosynovitis.First of all,we obtained targets of active ingredients of Rhizoma Corydalis and disease from various databases.Moreover we conducted core gene screening,enrichment analysis,and molecular docking.The screening showed that Rhizoma Corydalis had 16 active ingredients for the treatment of tenosynovitis.IL6 and TNF were the core genes with high degrees and the most involved in pathways,mainly including AGE-RAGE signaling pathway in diabetic complications,IL-17 signaling pathway,rheumatoid arthritis,etc.The molecular docking results showed that quercetin had a better combination with IL6 and TNF.This study predicted that Rhizoma Corydalis can treat tenosynovitis through multiple components and multiple pathways,which provided ideas for exploring more pharmacological effects of Rhizoma Corydalis.